Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $6.5 million.

  • GeneDx Holdings' Depreciation & Amortization (CF) rose 9.19% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 6.28%. This contributed to the annual value of $22.0 million for FY2024, which is 34.92% down from last year.
  • As of Q3 2025, GeneDx Holdings' Depreciation & Amortization (CF) stood at $6.5 million, which was up 4.57% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Depreciation & Amortization (CF) ranged from a high of $34.0 million in Q4 2022 and a low of $4.9 million during Q1 2021.
  • For the 3-year period, GeneDx Holdings' Depreciation & Amortization (CF) averaged around $6.7 million, with its median value being $6.1 million (2023).
  • In the last 5 years, GeneDx Holdings' Depreciation & Amortization (CF) surged by 487.40% in 2022 and then plummeted by 82.10% in 2023.
  • Over the past 5 years, GeneDx Holdings' Depreciation & Amortization (CF) (Quarterly) stood at $5.8 million in 2021, then surged by 487.40% to $34.0 million in 2022, then slumped by 82.10% to $6.1 million in 2023, then fell by 8.80% to $5.6 million in 2024, then climbed by 9.19% to $6.5 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $6.5 million for Q3 2025, versus $6.2 million for Q2 2025 and $5.7 million for Q1 2025.